Synonyms: Leptina; OB protein.
Cyrillic synonym: Лептин.


Leptin, an endogenous peptide hormone produced mainly by white adipocytes in adipose tissue, is involved in the long-term maintenance of body-weight through regulation of food intake and energy expenditure. Leptin has a negative feedback effect on hypothalamic control of neurotransmitters involved in the control of appetite: thus, an increase in adipose tissue mass results in an increase in leptin concentrations that in turn suppresses expression of appetite stimulatory peptides and vice versa. Mutations of either the leptin receptor or the ob gene that encodes the leptin protein result in failure of leptin’s control over appetite producing forms of morbid early-onset obesity. However, it is not clear that common obesity is associated with similar genetic mutations or, as also postulated, is associated with functional leptin resistance caused by sustained high leptin concentrations. Leptin is produced in other tissues, and studies have suggested additional functions and properties including modulation of neuroendocrine, immune, and reproductive processes. The potential role of leptin in a variety of disease states including syndromes of insulin resistance, auto-immune diseases, and cardiovascular disorders is also being studied. Replacement therapy with recombinant leptin is under investigation in the management of obesity as well as some other disorders including generalised lipodystrophy and hypothalamic amenorrhoea secondary to energy deficits or low body-weight.
1. Hukshorn CJ, et al. Weekly subcutaneous pegylated recombinant native human leptin (PEG-OB) administration in obese men. J Clin Endocrinol Metab 2000; 85: 4003–4009
2. Oral EA, et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med 2002; 346: 570–8
3. Proietto J, Thorburn AW. The therapeutic potential of leptin. Expert Opin Invest Drugs 2003; 12: 373–8
4. Veniant MM, LeBel CP. Leptin: from animals to humans. Curr Pharm Des 2003; 9: 811–8
5. Cochran E, et al. Efficacy of recombinant methionyl human leptin therapy for the extreme insulin resistance of the RabsonMendenhall syndrome. J Clin Endocrinol Metab 2004; 89: 1548–54
6. Javor ED, et al. Proteinuric nephropathy in acquired and congenital generalized lipodystrophy: baseline characteristics and course during recombinant leptin therapy. J Clin Endocrinol Metab 2004; 89: 3199–3207
7. Ebihara K, et al. Long-term leptin-replacement therapy for lipoatrophic diabetes. N Engl J Med 2004; 351: 615–6
8. Welt CK, et al. Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med 2004; 351: 987–97
9. Bell-Anderson KS, Bryson JM. Leptin as a potential treatment for obesity: progress to date. Treat Endocrinol 2004; 3: 11–18
10. Chan JL, Mantzoros CS. Role of leptin in energy-deprivation states: normal human physiology and clinical implications for hypothalamic amenorrhoea and anorexia nervosa. Lancet 2005; 366: 74–85
11. Zelissen PM, et al. Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults: a randomized, placebo-controlled trial. Diabetes Obes Metab 2005; 7: 755–61
12. Brennan AM, Mantzoros CS. Drug insight: the role of leptin in human physiology and pathophysiology — emerging clinical applications. Nat Clin Pract Endocrinol Metab 2006; 2: 318–27
13. Ebihara K, et al. Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. J Clin Endocrinol Metab 2007; 92: 532–41
14. Chan JL, et al. Pharmacokinetics of recombinant methionyl human leptin after subcutaneous administration: variation of concentration-dependent parameters according to assay. J Clin Endocrinol Metab 2007; 92: 2307–11.
Published May 08, 2019.